SymBio Pharmaceuticals

TYO: 4582

JPY16142.1m market cap

JPY181 last close

SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio’s branded formulation of bendamustine HCl. Rigosertib was in-licensed from Onconova.

Investment summary

SymBio is a speciality pharma focused on Asia-Pacific markets and has in-licensed two orphan blood cancer products. Treakisym iv was approved for r/r low-grade NHL/MCL in 2010 and in 2016 for CLL and first-line low-grade NHL/MCL; the additional approvals saw in-market Treakisym sales increase 12% in 2018, following 61% growth in 2017 (NHI price basis). SymBio has in-licensed liquid formulations for injection that will give Treakisym patent protection to 2031; a clinical trial is underway of the rapid-infusion liquid formulation, which would reduce Treakisym infusion time from 60 minutes to 10. A Phase III trial of Treakisym in r/r diffuse large B-cell lymphoma completed enrolment in April. Rigosertib iv is in development for r/r HR-MDS and is in a pivotal Phase III global study in 360 patients; SymBio is enrolling patients in Japan and aims for potential filing in 2021. SymBio intends to participate in a planned global trial of high-dose oral rigosertib in untreated HR-MDS.

Y/E Dec
Revenue (¥m)
EBITDA (¥m)
PBT (¥m)
EPS (fd) (¥)
P/E (x)
P/CF (x)
2017A 3444.0 (3917.0) (3977.0) (79.8) N/A N/A
2018A 3836.0 (2621.0) (2749.0) (41.4) N/A N/A
2019E 4109.0 (3664.0) (3679.0) (41.0) N/A N/A
2020E 3293.0 (5273.0) (5303.0) (54.5) N/A N/A
Last updated on 17/05/2019
Industry outlook

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operating leverage.

Last updated on 17/05/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (¥m) 1172
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (14.6) (5.7) (0.6)
Relative* (10.4) (4.3) 15.7
52-week high/low ¥272.0/¥116.0
*% relative to local index
Key management
Fuminori Yoshida Representative Director, President & CEO
Kazuo Asakawa Corporate Officer
Kenji Murata Corporate Officer

Content on SymBio Pharmaceuticals